目的 探讨康柏西普玻璃体腔注射对糖尿病视网膜病变(DR)患者视力的影响。方法 选择2014年5月-2016年5月我 院收治的DR患者104例，以随机数字表将其分为对照组与研究组，每组各52例。对照组应用曲安奈德一次性玻璃 体腔注射药物治疗，研究组应用康柏西普一次性玻璃体腔注射药物治疗。结果 研究组治疗后N1波潜伏期及视 网膜厚度均低于对照组(P<0.05)；最佳矫正视力高于对照组(P<0.05)。研究组并发症发生率3.85%，高于对照组 15.38%(P<0.05)。结论 康柏西普玻璃体腔注射对DR患者视力具有积极的促进作用，安全可靠，适于临床推广。

Objective To study the effects of conbercept intravitreal injection on visual acuity of diabetic retinopathy (DR) patients. Methods A total of 104 cases DR in our hospital from May 2014 to May 2016 were rolled into the study, with random number table it can be divided into control group and research group, 52 cases in each group. The control group used triamcinolone acetonide disposable intravitreal injection drug treatment, the research group applied conbercept of disposable intravitreal injection drugs. Results After treatment,the N1 wave incubation period and the thickness of the retina of the research group is lower than the control group (P<0.05). The best corrected visual acuity is higher than the control group (P<0.05). The complication rate of the research group 3.85%, higher than the control group 15.38% (P<0.05). Conclusion The conbercept intravitreal injection has positive effect on vision in patients with DR,it’s safe and reliable, and suitable for clinical promotion.